Cart
sales@molnova.com
Home - Products - Apoptosis - NF-κB - Edasalonexent

Edasalonexent

CAS No. 1204317-86-1

Edasalonexent( CAT-1004 | CAT1004 )

Catalog No. M10746 CAS No. 1204317-86-1

Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 267 Get Quote
50MG 1224 Get Quote
100MG 1674 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Edasalonexent
  • Note
    Research use only, not for human use.
  • Brief Description
    Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
  • Description
    Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA); significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever DMD model; Edasalonexent is hydrolyzed by FAAH to release salicylic acid and DHA intracellularly and to suppress activated NF-κB.Other Indication Phase 2 Clinical.
  • In Vitro
    Edasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retrieverduchenne muscular dystrophy (DMD) model.
  • In Vivo
    The treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury.
  • Synonyms
    CAT-1004 | CAT1004
  • Pathway
    Apoptosis
  • Target
    NF-κB
  • Recptor
    NF-κB
  • Research Area
    Other Indications
  • Indication
    Other Disease

Chemical Information

  • CAS Number
    1204317-86-1
  • Formula Weight
    490.688
  • Molecular Formula
    C31H42N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 120 mg/mL (244.56 mM)
  • SMILES
    O=C(NCCNC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)C1=CC=CC=C1O
  • Chemical Name
    N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Donovan JM, et al. J Clin Pharmacol. 2017 May;57(5):627-639. 2. Vu CB, et al. J Med Chem. 2016 Feb 11;59(3):1217-31.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • A922500

    A922500 is an inhibitor for human and mouse DGAT-1 with IC50 of 7 nM and 24 nM, respectively, good selectivity over related acyltransferases, hERG, and a panel of anti-targets.

  • Ergolide

    Ergolide inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of NF-κB.?

  • B022

    B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins.

Sign In Join Free